Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides are rare systemic diseases that usually occur in adulthood. They comprise granulomatosis with polyangiitis (GPA, Wegener’s), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome). Their clinical presentation is often heterogeneous, with frequent involvement of the respiratory tract, the kidney, the skin and the joints. ANCA-associated vasculitis is rare in childhood but North-American and European cohort studies performed during the last decade have clarified their phenotype, patterns of renal involvement and their prognostic implications, and outcome. Herein, we review the main clinical and therapeutic aspects of childhood-onset ANCA-associated vasculitis, and provide preliminary data on demographic characteristics and organ manifestations of an Italian multicentre cohort.
Fibroinflammatory diseases are a group of rare pathologies in which the hallmark is the exuberant deposition of fibrotic tissue and inflammatory cellular infiltrates, characteristic of the specific disease. A sclerotic mass develops within soft tissues and/or organs, damaging and replacing them, with effects ranging from asymptomatic to life-threatening clinical manifestations. The kidneys and urinary tract can be involved in some of these diseases, which can lead to acute kidney injury, chronic kidney disease, and even end-stage kidney disease. IgG4-related disease, retroperitoneal fibrosis, and Erdheim–Chester disease are the three fibroinflammatory disorders that can involve the kidneys. Only a timely and accurate collection of clinical, radiological, metabolic, laboratory, and histological data allows prompt diagnosis and targeted treatment of these pathologies, allowing the stoppage of the evolution of renal and systemic manifestations, which can lead to complete remission. The epidemiology, clinical and histological features, and management of these conditions are herein described in a narrative fashion.
INTRODUCTION AND AIMS: Renal involvement in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is common and usually occurs in 70% of patients with granulomatosis with polyangiitis(GPA) and in almost 100% of patients with microscopic polyangiitis (MPA). Renal involvement in AAV is characterized by rapidly progressive renal failure and histologically by necrotizing crescentic glomerulonephritis. Anecdotal cases of AAV with slower progression to end-stage renal disease (ESRD) have been reported. The purpose of this study is to describe a particular subset of AAV patients with slow renal progression.
The kidney biopsy is the cornerstone of prognostication in lupus nephritis, yet which features predict renal outcome—and which kind—remains incompletely defined. This narrative review relates eight histological axes to two families of renal outcome defined a priori: soft outcomes (renal flare/relapse and response/remission) and hard outcomes (doubling of serum creatinine, sustained decline in estimated glomerular filtration rate, and end-stage kidney disease; death is considered a competing, patient-level outcome). The axes span the ISN/RPS classification and its 2018 revision, individual glomerular and tubulointerstitial lesions, NIH activity and chronicity indices, lupus podocytopathy, lupus vasculopathy, antiphospholipid-antibody nephropathy, thrombotic microangiopathy and repeat biopsy. Across them, a consistent asymmetry emerges, although it is often not reproducible between studies. Chronicity—especially tubulointerstitial damage—predicts hard outcomes, whereas the activity index as a whole predicts response and flare. Cellular crescents and fibrinoid necrosis, active lesions that can signal hard outcomes, are the exceptions. Whether chronicity adds to baseline kidney function remains unsettled. Several prognostically important entities lie outside the proliferative classification; immune-deposit burden is largely diagnostic; and repeat histology adds information beyond the baseline biopsy. A recurring caveat is the therapeutic era, which modifies the very lesions scored.